Why Wegovy Has Real Benefits Over Ozempic for Weight Loss

Step 1: Understand what the licence actually means in practice

When the MHRA licenses a medicine, it is approving a specific product, at specific doses, for a specific population, based on the clinical trial data submitted for that exact use. Wegovy's licence was built on the STEP programme, trials designed around weight management as the primary outcome. Ozempic's licence was built on the SURPASS and SUSTAIN programmes, where the primary outcome was glycaemic control in people with type 2 diabetes.

This is not a paperwork difference. The doses are different. The titration schedules are different. The patient populations studied are different. Prescribing Ozempic to someone without diabetes, for weight loss, means using it in a way the regulator has not evaluated and approved. That is what off-label means. For the prescriber, it carries additional professional responsibility. For the patient, it means the product in their hands was not tested at that dose for their goal.

You can read the MHRA's position on this clearly laid out in the NHS patient information page for semaglutide, which distinguishes the two products explicitly. The starting point for any honest comparison is that distinction.

Step 2: See how the dose difference changes what the medicine can do

Ozempic's highest approved dose in the UK is 2mg weekly. That ceiling matters because dose-response is real with semaglutide, higher doses produce greater appetite suppression and, in trial populations, greater average weight reduction. Wegovy's maintenance dose sits at 2.4mg, with the MHRA approving a dedicated 7.2mg single-dose pen in April 2026 for adults with obesity, extending that ceiling further still.

The practical consequence: even if a GP were to prescribe Ozempic off-label for weight management, the patient would never reach the dose level at which the weight-loss evidence was generated. The roughly 15% average body-weight reduction seen in the STEP 1 trial was produced at the 2.4mg maintenance dose, a dose Ozempic simply does not reach.

There is also the question of pen design. Wegovy's pens are produced and labelled for weight management. The titration steps built into the Wegovy pathway (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) were designed with tolerability for a weight-management population in mind, not diabetes management. Pull a Wegovy pen out of the fridge door in the morning and the dose printed on it reflects exactly where you are in a pathway designed for your goal. That alignment matters for adherence and for prescriber oversight.

Step 3: Recognise that the shortage context drove the confusion, and what it left behind

Much of the public curiosity about Ozempic for weight loss stems from a period of significant Wegovy supply shortages across Europe, during which some clinicians and patients looked at Ozempic as a practical workaround. That period left behind a common misconception: that the two products are equivalent and interchangeable, with Ozempic simply being the cheaper or more available version.

They are not equivalent. They were developed with different populations and different endpoints in mind, they carry different licensed indications, and they reach different dose ceilings. The question of whether Wegovy and Ozempic are the same deserves a full answer, because conflating them carries real risk, both the risk of under-dosing relative to what the evidence supports, and the risk of a prescriber taking on off-label liability without a clear clinical rationale.

For a broader look at what semaglutide as a class is approved to do, our semaglutide overview covers the full licensing picture in plain language.

What is actually licensed for weight management in the UK, and where to go next

Two injectable treatments hold UK licences specifically for weight management in adults: Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). Mounjaro is a dual GIP and GLP-1 receptor agonist (the only medicine in its class currently licensed in the UK) and produced greater average weight reduction than semaglutide 2.4mg in the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in 2025. Which of the two is more appropriate depends on individual clinical factors, and a prescriber works through those with you.

There is also now an oral option: the Wegovy tablet received MHRA approval in June 2026, making it the first oral GLP-1 medicine licensed in the UK for weight management. For some people, a once-daily tablet fits their routine better than a weekly injection.

Ozempic does not sit in this list. It is a diabetes medicine. If weight management is your goal, it is not the right starting point, and a responsible prescriber will say so.

You can explore the specific advantages of the licensed injectable in more detail through our page on semaglutide's benefits for weight management, or read about the broader effects Wegovy can have beyond weight reduction. If cost is on your mind, our Wegovy pricing page covers what private treatment typically involves. A useful companion read is our overview of the benefits of taking semaglutide, which looks at the evidence across the licensed weight-management indication rather than any off-label use.

If you'd like to find out which licensed treatment suits your situation, our prescribers review every consultation personally, the same day, for orders placed before 12pm Monday to Friday. Start your free consultation and a GPhC-registered prescriber will assess your full picture, not just your BMI.